Standard InChI: InChI=1S/C20H12O6/c21-20-12-5-10-2-4-15-19(26-9-24-15)18(10)17(13(12)7-22-20)11-1-3-14-16(6-11)25-8-23-14/h1-6H,7-9H2
Standard InChI Key: JUBRYHUFFFYTGR-UHFFFAOYSA-N
Associated Targets(Human)
CCRF-CEM 65223 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
MT2 2907 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
A2058 690 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
HepG2 2.2.15 869 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Associated Targets(non-human)
Hepatitis B virus 7925 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Hepatitis C virus 23859 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Human alphaherpesvirus 1 11089 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Human alphaherpesvirus 2 4932 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Human gammaherpesvirus 4 1538 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Mus musculus 284745 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Artemia salina 1320 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Aedes aegypti 630 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Molecule Features
Natural Product: Yes
Oral: No
Chemical Probe: No
Parenteral: No
Molecule Type: Small molecule
Topical: No
First In Class: No
Black Box: No
Chirality: No
Availability: No
Prodrug: No
Drug Indications
MESH ID
MESH Heading
EFO IDs
EFO Terms
Max Phase for Indication
References
Mechanisms of Action
Mechanism of Action
Action Type
target ID
Target Name
Target Type
Target Organism
Binding Site Name
References
Properties
Molecular Weight: 348.31
Molecular Weight (Monoisotopic): 348.0634
AlogP: 3.63
#Rotatable Bonds: 1
Polar Surface Area: 63.22
Molecular Species: NEUTRAL
HBA: 6
HBD: 0
#RO5 Violations: 0
HBA (Lipinski): 6
HBD (Lipinski): 0
#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.32
CX Basic pKa:
CX LogP: 3.41
CX LogD: 3.41
Aromatic Rings: 3
Heavy Atoms: 26
QED Weighted: 0.63
Np Likeness Score: 1.00
References
1.Yeo H, Li Y, Fu L, Zhu JL, Gullen EA, Dutschman GE, Lee Y, Chung R, Huang ES, Austin DJ, Cheng YC.. (2005) Synthesis and antiviral activity of helioxanthin analogues., 48 (2):[PMID:15658867][10.1021/jm034265a]
2.He K, Zeng L, Shi G, Zhao GX, Kozlowski JF, McLaughlin JL.. (1997) Bioactive compounds from Taiwania cryptomerioides., 60 (1):[PMID:9014350][10.1021/np960513c]
4.Janmanchi D, Tseng YP, Wang KC, Huang RL, Lin CH, Yeh SF.. (2010) Synthesis and the biological evaluation of arylnaphthalene lignans as anti-hepatitis B virus agents., 18 (3):[PMID:20061158][10.1016/j.bmc.2009.12.038]
5.Janmanchi D, Lin CH, Hsieh JY, Tseng YP, Chen TA, Jhuang HJ, Yeh SF.. (2013) Synthesis and biological evaluation of helioxanthin analogues., 21 (7):[PMID:23465436][10.1016/j.bmc.2012.11.037]
7.Hajdu Z, Haskó J, Krizbai IA, Wilhelm I, Jedlinszki N, Fazakas C, Molnár J, Forgo P, Hohmann J, Csupor D.. (2014) Evaluation of lignans from Heliopsis helianthoides var. scabra for their potential antimetastatic effects in the brain., 77 (12):[PMID:25479041][10.1021/np500508y]
8.Pei Y, Wang C, Yan SF, Liu G.. (2017) Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection., 60 (15):[PMID:28383274][10.1021/acs.jmedchem.6b01442]